Literature DB >> 27863412

Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer.

Wei Zhang1, Zhifen Zhang1.   

Abstract

Recent studies explored XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer (OC) risk. However, the association between these two single nucleotide polymorphisms and OC risk remains conflicting. Thus, we conducted a comprehensive systematic review and meta-analysis to investigate the association. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. 15 case-control studies published in 11 papers including 4,757 cases and 8,431 controls were included in this meta-analysis. No associations were obtained between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk. Stratification analyses of Hardy-Weinberg equilibrium status indicated that rs3218536 polymorphism was associated with the decreased risk of OC when in analysis of combined HWE positive studies. In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.

Entities:  

Keywords:  ERCC2; XRCC2; meta-analysis; ovarian cancer; single nucleotide polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27863412      PMCID: PMC5349940          DOI: 10.18632/oncotarget.13361

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Ovarian cancer (OC), leading cause of gynaecologic cancer death, is the second most common gynaecologic cancer [1]. OC is mainly classified into four subtypes: serous, endometrioid, mucinous, and clear cell. Most of malignant OCs are of epithelial origin [2]. To date, the pathogenesis of OC still remains unclear. Multiple factors including age, family history of OC, gravidity, genetic and other environmental factors might be account for the etiology of OC [3, 4]. The known ovarian cancer susceptibility genes explain nearly 40% of the excess familial risk of OC [5]. DNA repair system takes part in maintaining the genomic integrity. The repair process usually contains two stages: the excision of lesion and the repair synthesis [6]. The repair system acts by mismatch repair (MMR), nucleotide excision repair (NER), and base-excision repair (BER). The repair by recombination removes a host of serious DNA lesions, encompassing double-stranded breaks (DSBs). These breaks induce a loss of some chromosomes and causes translocation of genetic material between them. Studies provided evidence to support the association between DSBs repair gene variants and ovarian cancer [7, 8]. The X-ray cross-complementing (XRCC) genes are DNA repair genes. These genes are associated with the DNA damage processing and genetic stability [9]. Studies have demonstrated that XRCC2 gene participates in homologous recombination of DNA [10]. Excision repair cross-complimentary group 2 (ERCC2), called xeroderma pigmentosum complementation group D (XPD), is involved in the NER pathway. ERCC2 removes certain DNA cross-links, ultraviolet photolesions, and bulky chemical adducts [11]. We hypothesized that those DNA repair genes (XRCC2 and ERCC2) are significantly associated with the risk of OC. A number of studies [6, 9, 11–18] investigated the relationship between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC susceptibility, but with conflicting results. Thus, we conducted a comprehensive meta-analysis to explore the possible association between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk.

RESULTS

Characteristics of the included studies

We yielded 97 citations after initial searching. 34 citations were removed after removing duplicates. After screening the titles and abstracts, 36 citations were excluded. 27 citations were selected for further full text review. 16 citations were excluded: 6 were meta-analyses [19-24]; 6 not case-control studies [25-30]; 3 investigated other polymorphisms [14, 31, 32]; 1 did not provide detailed genotyping data [33]. We finally included 11 eligible citations [6, 9, 11–18] including 15 studies (4,757 cases and 8,431 controls) in this meta-analysis. Selection for eligible studies included in this meta-analysis was presented in Figure 1. The characteristics of included studies are summarized in Table 1. The Newcastle-Ottawa Scale (NOS) scores of all included studies ranged from 5 to 7 scores.
Figure 1

Selection for eligible citations included in this meta-analysis

Table 1

Characteristics of included studies

Author and yearCountryGenotype methodSOCEthnicityCaseControlHWENOS
XRCC2 rs3218536Arg/ArgArg/HisHis/HisArg/ArgArg/HisHis/His
Auranen_2005aUKTaqManPBCaucasian6299827041299Y6
Auranen_2005bDenmarkPCRPBCaucasian260541331685Y6
Auranen_2005cUSAPCRPBCaucasian238310484752Y7
Auranen_2005dUKPCRPBCaucasian25123115382676Y6
Webb_2005aAustraliaPCR-RFLPHBCaucasian3646338021408Y5
Webb_2005bAustraliaPCR-RFLPHBMixed8752150162Y7
Beesley_2007AustraliaMALDI-TOFPBCaucasian79911776961157Y6
Mohamed_2013EgyptPCRHBCaucasian65836166024N6
Michalska_2016PolandPCR-RFLPPBCaucasian12080500180400120N7
ERCC2 rs13181Lys/LysLys/GlnGln/GlnLys/LysLys/GlnGln/Gln
Costa_2007PortugalPCR-RFLPHBCaucasian554922959512Y7
Bernard-Gallon_2008FranceTaqManHBCaucasian13119119446430Y5
Jakubowska_2010PolandPCRHBCaucasian58652210012357Y6
Mohamed_2013EgyptPCRHBCaucasian325414553510Y7
Monteiro_2014BrazilPCR-RFLPHBCaucasian3336137303Y6
Michalska_2015PolandPCR-RFLPPBCaucasian62643049624094Y6

SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle-Ottawa Scale

SOC, source of controls; PB, population-based controls; HB, hospital-based controls; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle-Ottawa Scale

Quantitative synthesis

As presented in Table 2, we obtained no significant association between XRCC2 rs3218536 or ERCC2 rs13181 (dominant: OR, 1.45; 95% CI, 0.99–2.14, P = 0.058, Figure 2) polymorphisms and the risk of OC. Stratification analyses were conducted according to HWE status, ethnicity and source of control (SOC). Our data indicated that XRCC2 rs3218536 polymorphism was significantly associated with a decreased risk of OC among HWE positive studies (Table 3). Regarding stratification analysis by SOC, we detected ERCC2 rs13181 polymorphism increased the risk of OC in population-based study (dominant model, Figure 3), while no association was found in both population-based and hospital-based studies. No significant association was obtained about rs3218536 polymorphism when performing stratification analyses by ethnicity.
Table 2

Meta-analysis of association between ERCC2 rs13181, XRCC2 rs3218536 polymorphisms and OC risk

Genetic modelsOR(95%CI)P-valueP for heterogeneityI2 (%)Model
rs13181
Allele1.45(0.83,2.54)0.188< 0.00193.8Random
Dominant1.45(0.99,2.14)0.0580.01066.7Random
Recessive1.56(0.49,4.93)0.447< 0.00195.0Random
rs3218536
Allele1.05(0.61,1.82)0.852< 0.00196.4Random
Dominant0.96(0.74,1.24)0.759< 0.00175.0Random
Recessive1.11(0.34,3.63)0.862< 0.00191.7Random
Figure 2

Forest plot shows odds ratio for the associations between ERCC2 rs13181 polymorphism and OC risk (Dominant model)

Table 3

Summary of the subgroup analyses in this meta-analysis

ComparisonCategoryCategoryStudiesOR (95% CI)P-value
rs3218536
AlleleSOCPB61.04(0.49,2.19)0.926
HB31.13(0.77,1.66)0.535
HWEPositive70.84(0.74,0.95)0.006
Negative22.57(1.03,6.38)0.042
EthnicityCaucasian81.08(0.61,1.94)0.783
Asian10.79(0.35,1.78)0.577
DominantSOCPB60.91(0.67,1.24)0.556
HB31.17(0.59,2.33)0.649
HWEPositive70.83(0.73,0.95)0.007
Negative21.74(1.36,2.24)<0.001
EthnicityCaucasian80.98(0.75,1.28)0.887
Asian10.67(0.27,1.67)0.390
RecessiveSOCPB60.92(0.15,5.80)0.932
HB31.57(0.92,2.69)0.098
HWEPositive70.69(0.37,1.26)0.225
Negative24.74(0.73,30.96)0.104
EthnicityCaucasian81.05(0.29,3.73)0.943
Asian11.80(0.25,13.02)0.558
rs13181
AlleleSOCHB51.19(0.89,1.59)0.248
PB13.61(2.93,4.45)<0.001
DominantSOCHB51.41(0.86,2.32)0.168
PB11.71(1.20,2.43)0.003
RecessiveSOCHB51.13(0.58,2.19)0.726
PB18.62(6.33,11.75)<0.001
Figure 3

Stratification analyses by source of control between ERCC2 rs13181 polymorphism and OC risk (Dominant model)

We assessed sensitivity by omitting each study once at a time in every genetic model for XRCC2 rs3218536 or ERCC2 rs13181 polymorphisms. The pooled ORs for the effects about these two polymorphisms indicated that our data about the two SNPs were stable and trustworthy (rs3218536: recessive model, Figure 4; rs13181: dominant model, Figure 5). Begg's test was used to evaluate the publication bias of this meta-analysis (rs3218536, allele: P = 0.764, dominant: P = 1.000, and recessive: P = 0.532; rs13181, allele: P = 0.573, dominant: P = 0.348, and recessive: P = 0.851). Our data revealed that there was no obvious publication bias for the two SNPs. Due to significant between-study heterogeneity among some genetic models, we conductedmeta-regression to explore whether ethnicity, HWE status and SOCwere the resources of heterogeneity. However, our data suggested that ethnicity, HWE status and SOC did not seem to be responsible for the heterogeneity (data not shown).
Figure 4

Sensitivity analysis about XRCC2 rs3218536 polymorphism and OC risk (Recessive model)

Figure 5

Sensitivity analysis about ERCC2 rs13181 polymorphism and OC risk (Dominant model)

DISCUSSION

DNA repair systems are important for protecting against mutations and are necessary for maintaining the integrity of the genome. Many identified DNA repair genes are recognized to have genetic variations in humans [34]. DNA repair gene polymorphisms may alter the protein function. They can also cause reduction in DNA repair capacity, which may result in genetic instability and carcinogenesis [35, 36]. DNA damage influences mitosis and the isolation of chromosomes, which can be solved by homologous recombination repair (HRR) [37]. HRR is a pivotal pathway to repair the DSBs and maintain the genetic stability [38]. XRCC2 is involved in the HRR pathway and associated with DNA DSB repair and genomic stability [38, 39]. ERCC2 is one of seven nucleotide excision repair enzymes. ERCC2 could cause Xeroderma Pigmentosum when mutated in germ line. ERCC2 is involved in DNA repair, specifically in nucleotide excision repair. It functions in various types of DNA lesions [12]. Both XRCC2 and ERCC2 are identified as DNA repair genes. A host of studies [6, 9, 11–18] have explored the associations between XRCC2 rs3218536 or ERCC2 rs13181 gene polymorphisms and OC risk. But they provided inconsistent results. These studies were conflicting and inconclusive may due to different ethnic populations, clinical heterogeneity, and small sample sizes. As a result, we conducted a meta-analysis to investigate the association. We found no evidence for an association with XRCC2 rs3218536 or ERCC2 rs13181 polymorphism. Stratification analyses of HWE status revealed that XRCC2 rs3218536 polymorphism was significantly associated with a decreased risk of OC in analysis of HWE positive studies. Studies conform to HWE, indicating control subjects were representative of the general population. Studies with deviation from HWE are prone to false positive results [40]. Further investigations are urgent to confirm the findings of stratification analyses. Previous meta-analysis [20, 23] demonstrated the association with XRCC2 rs3218536 polymorphism, but with contradictory conclusions. Shi et al. found rs3218536 polymorphism reduced the risk of OC [23], while Zhai et al. indicated this SNP increased the risk of ovarian cancer [20]. However, our data suggested that this SNP was not associated with the risk of OC. Compared with previous meta-analysis, this meta-analysis included a new Polish study containing 700 cases and 700 controls. It is well recognized that the association between SNPs in genes with diseases is greatly affected by the number of subjects. Our study has larger sample size, indicating that our data are more robust. Stratification analyses of rs3218536 polymorphism by ethnicity suggested that no association was obtained with Caucasian population or mixed population. To seek the sources of high heterogeneity in this meta-analysis, we conducted meta-regression analysis, stratification analyses, and sensitivity analysis. Meta-regression analysis of ethnicity, HWE status and SOC was conducted. Our data confirmed that ethnicity, HWE status and SOC were not the sources of heterogeneity. Sensitivity analysis about XRCC2 rs3218536 polymorphism indicated the Polish study [6] may be the source of heterogeneity. We found the heterogeneity reduced substantially in three genetic models (Allele, I2 = 48.9%; Dominant, I2 = 42.0%); Recessive, I2 = 19.6%) when we excluded this Polish study. The reasons of high heterogeneity may due to different ethnic populations, clinical heterogeneity, and small sample sizes. However, potential limitations should be addressed in this meta-analysis. First, due to limited data, we could not perform further stratification analyses of other populations, such as Asians. Second, our results were based on unadjusted estimates for confounding factors, which might influence the final findings. Third, we could not assess potential gene-gene and gene-environment interactions. Fourth, the sample sizes of subgroup analysis are limited. These stratification analyses were based on small numbers and any association is likely to be due to chance. Fifth, high heterogeneity existed in some genetic models of this meta-analysis. In summary, this meta-analysis suggests that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with OC susceptibility. Stratification analysis indicates that XRCC2 rs3218536 polymorphism was significantly associated with a decreased risk of OC when in analysis of HWE positive studies. Further studies are necessary to validate whether these two SNPs is associated with OC susceptibility in other ethnic groups.

MATERIALS AND METHODS

Literature search and inclusion criteria

We systematically searched the PubMed, and Embase to identify studies through September 13, 2016. The following search terms were used: “ovarian cancer,” “ovarian neoplasm,” “ovarian carcinoma,” “ERCC2,” “XPD,” “XRCC2” and “polymorphism”. Other potential omitted studies were identified by hand screening. The inclusion criteria of studies were as following: (1) studies that evaluated the association between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk, (2) study provided sufficient data to calculate the odds ratios (ORs) and 95% confidence intervals (CIs), and (3) case-control study.

Data extraction and quality assessment

Data was extracted from all eligible studies by two authors. The extracted information from all eligible studies including: name of first author, publication year, country, ethnicity, source of control, and genotype numbers of cases and controls. Two authors independently conducted the extraction of data. We assessed the study quality according to the NOS [41]. All disagreements were resolved by discussion until reaching consent.

Statistical analysis

The crude ORs and 95%CIs were used to assess the strength of associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk. Stratification analysis was carried out by HWE status, ethnicity and SOC. When a Q test indicated P < 0.1 or I2 > 50% indicated heterogeneity across studies, a random-effect model was used. Otherwise, the fixed-effects model was applied [42]. Pooled ORs were calculated for allele model, dominant model, and recessive model. We performed leave-one-out sensitivity analysis to evaluate the stability of the overall results. We assessed the departure from the HWE in the controls using Pearson's χ2 test. Begger's linear regression test was used to detect the potential publication bias [43]. Meta-regression analysis of ethnicity, HWE status and SOC was performed to seek the main sources of the heterogeneity. All statistical analyses were performed using the Stata 11.0 software (STATA Corporation, College Station, TX, USA).
  43 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer.

Authors:  Sandra Costa; Daniela Pinto; Deolinda Pereira; André Vasconcelos; Carlos Afonso-Lopes; Teresa Osório; Carlos Lopes; Rui Medeiros
Journal:  Cancer Lett       Date:  2006-05-04       Impact factor: 8.679

3.  Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.

Authors:  Nicole D Fleming; Hasmik Agadjanian; Hoorig Nassanian; Carl W Miller; Sandra Orsulic; Beth Y Karlan; Christine S Walsh
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

4.  Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.

Authors:  Penelope M Webb; John L Hopper; Beth Newman; Xiaoqing Chen; Livia Kelemen; Graham G Giles; Melissa C Southey; Georgia Chenevix-Trench; Amanda B Spurdle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

5.  An association between the -41657 C/T polymorphism of X-ray repair cross-complementing 2 (XRCC2) gene and ovarian cancer.

Authors:  Magdalena M Michalska; Dariusz Samulak; Beata Smolarz
Journal:  Med Oncol       Date:  2014-10-30       Impact factor: 3.064

6.  [Association of polymorphisms in glutathione-S-transferase and DNA repair genes with ovarian cancer risk in the Russian population].

Authors:  D V Khokhrin; A V Khrunin; A A Moiseev; V A Gorbunov; S A Limborskaia
Journal:  Genetika       Date:  2012-07

7.  Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and ovarian cancer in Polish women.

Authors:  Magdalena M Michalska; Dariusz Samulak; Hanna Romanowicz; Filip Jabłoński; Beata Smolarz
Journal:  Exp Mol Pathol       Date:  2016-01-19       Impact factor: 3.362

8.  Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention.

Authors:  William J Murdoch; James F Martinchick
Journal:  Exp Biol Med (Maywood)       Date:  2004-06

9.  Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer.

Authors:  Andreas Rump; Anna Benet-Pages; Steffen Schubert; Jan Dominik Kuhlmann; Ramūnas Janavičius; Eva Macháčková; Lenka Foretová; Zdenek Kleibl; Filip Lhota; Petra Zemankova; Elitza Betcheva-Krajcir; Luisa Mackenroth; Karl Hackmann; Janin Lehmann; Anke Nissen; Nataliya DiDonato; Romy Opitz; Holger Thiele; Karin Kast; Pauline Wimberger; Elke Holinski-Feder; Steffen Emmert; Evelin Schröck; Barbara Klink
Journal:  PLoS Genet       Date:  2016-08-09       Impact factor: 5.917

10.  Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis.

Authors:  Yazhou He; Yuanchuan Zhang; Chengwu Jin; Xiangbing Deng; Mingtian Wei; Qingbin Wu; Tinghan Yang; Yanhong Zhou; Ziqiang Wang
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

View more
  2 in total

Review 1.  Xeroderma Pigmentosum: Gene Variants and Splice Variants.

Authors:  Marie Christine Martens; Steffen Emmert; Lars Boeckmann
Journal:  Genes (Basel)       Date:  2021-07-29       Impact factor: 4.096

2.  Association of XRCC2 rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis

Authors:  Mahdieh Kamali; Sedigheh Hamadani; Hossein Neamatzadeh; Mahta Mazaheri; Masoud Zare Shehneh; Mitra Modaress Gilani; Fatemeh Haghighi
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.